Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
about
Targeted therapy for localized non-small-cell lung cancer: a reviewEGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancerPrognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma casesThe BATTLE to personalize lung cancer prevention through reverse migration.Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element.Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients.Personalizing lung cancer prevention through a reverse migration strategy.Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.How and when to use genetic markers for nonsmall cell lung cancer.Chronological changes in lung cancer surgery in a single Japanese institution.Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report.The evolving role of targeted therapy in early-stage and locally advanced non-small cell lung cancer.Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinibSurgery for NSCLC in the era of personalized medicine.Erlotinib in the first-line treatment of non-small-cell lung cancer.Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection.Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy.Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer.Adjuvant TKIs in NSCLC: what can we learn from RADIANT?Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4 years after sublobar resection for adenocarcinoma in situ: report of a case.Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis.Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature.Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors.
P2860
Q26741441-92826082-3F45-4FF1-A34A-F5F6F6BBAC62Q26778298-E0B41D7D-91D6-463A-997C-23013FD43BB1Q26863742-FD81299D-5040-40CF-965C-A19D9619A6B9Q27853213-B9DA5753-EAFC-4231-8EAE-4D4C6950E9DBQ35208501-3B6061F8-FEE0-418D-AE10-87E3F6E4E4C9Q35631635-FD09D942-AE48-409C-8D0F-A98744CB884FQ35771994-67E98308-5FE4-400D-A551-7B17BE0DF242Q35810510-E8D6B034-FA67-4026-B9FB-80BA467AB573Q36197300-1C03EAB6-5765-4552-95B0-2F8585E38F3AQ36524729-860EA4A6-3489-4EEC-A3D1-DA41BCD0F069Q37080513-A7B7D248-1088-4418-AAC9-DD2349404C58Q37458637-CE928D48-D502-4048-B97F-0F161C53AE03Q37588365-1D662AA1-BA6A-4F17-9F12-12939392D050Q37696710-0B753024-D584-456A-92AE-54E90E2367ABQ37696841-15D8E489-98FA-47EC-80A8-3B63F59B60E0Q37883955-987426EF-A51A-4ADE-8CC4-8257B5022251Q37915088-45570D6D-8E9C-41C8-87D4-F36C6B2CE620Q38084427-0DBDF76C-9AA8-49CE-9CBC-AC196557E580Q38101604-8EAA35CF-CEB8-4560-8960-0DE71EEE643DQ38352862-1C98BAFC-5866-43C1-9C43-B49F936A3FF7Q38390085-E88BED1C-5EBF-4EAD-A9B1-4DFD25E60648Q38400481-56BAD657-44C9-4A9D-9D27-A8E9DB3E39A5Q38486882-E891D9BC-BACB-4BE6-9F14-E59895DC9132Q38622807-BC1470F7-869E-4EC5-9B03-7344BC9679CEQ38717594-0AD9842E-94D3-4EE7-8EB8-FB0875662F45Q38831491-FD202D85-2E3B-4E43-AF3A-DEC126A9A019Q38906773-D1E08E59-7F91-4948-B1CA-6FD44F246035Q38991958-B03B661A-25DA-4742-B184-0C379550E355Q43073804-F9924C27-EBBA-4177-BE1C-A26BDCA9BA46Q47152564-9C897D95-577F-4DF2-9E34-B6C43928FBB8Q47423861-2BC8A466-0F06-4C8B-A9FE-111B67AFEB06Q48627805-8F0D5B4D-6356-4B28-87E9-0B86E15143AFQ52903632-FD1AEDD5-23DC-41B4-A09B-A59747F24B2BQ54311116-5AF07761-CF69-4883-9DAE-ED9E297FEED0Q54373981-69F3DD20-33FF-4AEE-AF9A-8D1CF832EFFEQ55067213-87F5782A-FE7E-4B53-89A5-94DDEEBC01C8Q55263540-10702FB7-8984-4730-9A2E-6269F2CE384FQ55280808-5E25E636-FBA9-4B71-B584-CD08C1AE0DBE
P2860
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact on disease-free surviva ...... mas that harbor EGFR mutations
@en
Impact on disease-free surviva ...... as that harbor EGFR mutations.
@nl
type
label
Impact on disease-free surviva ...... mas that harbor EGFR mutations
@en
Impact on disease-free surviva ...... as that harbor EGFR mutations.
@nl
prefLabel
Impact on disease-free surviva ...... mas that harbor EGFR mutations
@en
Impact on disease-free surviva ...... as that harbor EGFR mutations.
@nl
P2093
P2860
P1476
Impact on disease-free surviva ...... mas that harbor EGFR mutations
@en
P2093
Bernard J Park
Christopher G Azzoli
Junting Zheng
Mark G Kris
Maureen F Zakowski
Ronglai Shen
Sandra P D'Angelo
Yelena Y Janjigian
P2860
P304
P356
10.1097/JTO.0B013E318202BFFE
P577
2011-03-01T00:00:00Z